Danyang Huichuang Medical Equipment Co., Ltd, a China-based specialist in functional near-infrared spectroscopy (fNIRS), has reportedly secured over RMB 100 million (USD 13.7 million) in a Series B financing round. The funding round was led by Zhongke Haichuang, with additional contributions from Addor Capital, and existing investors Tsingyua Capital and Tao Capital. The proceeds are earmarked to enhance the development of fNIRS brain functional imaging products and to conduct clinical studies for transcranial light regulation products in degenerative diseases.
Company Background and Product Portfolio
Founded in 2016, Huichuang Med has established a robust product portfolio that includes a small portable device and the highest 157-channel whole brain area detection device in China. The company also offers NirSpark software, which is the first one-stop fNIRS data processing software on the market that does not require programming, marking a significant advancement in user accessibility and functionality.
Future Outlook and Investment Impact
The Series B funding is expected to significantly bolster Huichuang Med’s efforts in developing innovative fNIRS products, which have the potential to revolutionize brain imaging and treatment approaches for various neurological conditions. This investment underscores the growing interest and confidence from the investment community in the potential of fNIRS technology in healthcare.-Fineline Info & Tech
